| Literature DB >> 23506637 |
Bartłomiej Guzik1, Agnieszka Sagan, Dominik Ludew, Wojciech Mrowiecki, Maciej Chwała, Beata Bujak-Gizycka, Grzegorz Filip, Grzegorz Grudzien, Boguslaw Kapelak, Krzysztof Zmudka, Tomasz Mrowiecki, Jerzy Sadowski, Ryszard Korbut, Tomasz J Guzik.
Abstract
UNLABELLED: Aortic abdominal aneurysms (AAA) are important causes of cardiovascular morbidity and mortality. Oxidative stress may link multiple mechanisms of AAA including vascular inflammation and increased metalloproteinase activity. However, the mechanisms of vascular free radical production remain unknown. Accordingly, we aimed to determine sources and molecular regulation of vascular superoxide (O2(-)) production in human AAA. METHODS ANDEntities:
Keywords: Aortic abdominal aneurysm; Inflammation; NAD(P)H oxidase; Oxidant stress; Reactive oxygen species; Superoxide
Mesh:
Substances:
Year: 2013 PMID: 23506637 PMCID: PMC3819986 DOI: 10.1016/j.ijcard.2013.01.278
Source DB: PubMed Journal: Int J Cardiol ISSN: 0167-5273 Impact factor: 4.164
Clinical characteristics of patients from whom aortic specimens and/or plasma were obtained. CAD — coronary artery disease; BMI — body mass index; PAD — peripheral arterial disease; TIA — transient ischemic attacks; ACE-I — Angiotensin Converting Enzyme Inhibitor.
| Control group | AAA | p value | |
|---|---|---|---|
| N | 16 | 40 | |
| Age (mean ± SD) | 64.6 ± 6.9 | 65.7 ± 6.7 | 0.70 |
| Sex (M:F) | 12:4 | 36:4 | 0.14 |
| Smoking (n; %) | 12 (75%) | 28 (70%) | 0.70 |
| Hypertension (n; %) | 12 (75%) | 31 (77.5%) | 0.84 |
| Diabetes (n; %) | 1 (6.2%) | 3 (7.5%) | 0.87 |
| Hypercholesterolemia (n; %) | 10 (62.5%) | 26 (65%) | 0.86 |
| BMI | 29.7 ± 5.2 | 26.9 ± 3.3 | 0.60 |
| Cholesterol (mmol/L; mean ± SD) | 6.1 ± 1.5 | 6.3 ± 1.8 | 0.50 |
| CAD (n; %) | 16 (100%) | 36 (90%) | 0.18 |
| PAD, TIA (n; %) | 5 (31%) | 14 (35%) | 0.78 |
| Aspirin | 12 (75%) | 27 (68%) | 0.58 |
| ACE-I | 6 (37%) | 25 (62.5%) | 0.07 |
| β-Blocker | 9 (56%) | 14 (35%) | 0.14 |
| Statin | 10 (62.5%) | 24 (60%) | 0.86 |
Indicates factors which were exactly matched for the comparison of MDA between patients (data shown in Fig. 1).
Morphologic characteristics of studied aneurysms.
| Parameter | Average ± SD | ||
|---|---|---|---|
| Ultrasound assessment | Maximal AAA aortic size (L3) | mm | 64.5 ± 17.8 |
| Sub-diaphragmatic aortic size (L1) | mm | 26.0 ± 4.1 | |
| Enlargement ratio (L3/L1) | 2.4 ± 0.6 | ||
| Intraoperative assessment | Maximal size | mm | 69.2 ± 21.9 |
| AAA with thrombus | 77.5% | ||
Fig. 1Abdominal aortic aneurysm is associated with systemic oxidative stress. Panel A. Malondialdehyde (MDA) levels in plasma of subjects with AAA and patients without AAA (control group) with similar risk factor profile. Data are presented as median [10th–90th percentile]; (n = 16 in each group) Panel B. Plasma MDA levels in 16 patient pairs, matched exactly for age, sex, and major risk factors for atherosclerosis such as hypertension, hypercholesterolemia, smoking and diabetes.
Fig. 2Vascular superoxide production aortic segments from patients with AAA and without AAA. Panel A. Basal superoxide production was measured by LGCL (5 μmol/L) in intact segments of aorta obtained from aortic aneurysm at largest diameter point (n = 38) and from non-aneurysmatic segment (non AAA). Superoxide production was expressed in RLU/s/mg dw. Specificity for superoxide was investigated by pre-incubation with PEG-SOD (500 U/mL) or MnTBAP (25 μmol/L) *-p < 0.01 vs. nonAAA; **-p < 0.01 vs no inhibitor. Panel B. Histochemical in situ detection of superoxide by DHE staining of abdominal aorta sections obtained from AAA patient. Control sections were incubated with PEG-SOD (500 U/mL). Photograph is representative of n = 5 independent comparisons. A — indicates adventitial side of aortic section.
Fig. 3Sources of vascular superoxide anion in human abdominal aortic aneurysms. Panel A. Superoxide production was determined by LGCL (5 μmol/L) in intact aortic segments (n = 6), following a 30 minute incubation with various oxidase inhibitors: NADPH oxidase (apocynin, 300 μmol/L, not entirely specific), diphenyleneiodonium (DPI; 10 μmol/L); xanthine oxidase (allopurinol, 100 μmol/L), mitochondrial oxidases (rotenone, 100 μmol/L), cyclooxygenase (indomethacin, 10 μmol/L), nitric oxide synthase (L-NAME, 100 μmol/L) or iNOS (1400W, 2 μmol/L). Panel B. Effects of protein kinase C inhibition on superoxide production in AAA. Basal (left graph) and NADPH (100 μmol/L) stimulated (right graph) superoxide production was measured in intact segments of AAA using LGCL (5 μmol/L). Adjacent segments were pre-incubated for 30 min with or without an inhibitor and luminescence was measured in the absence/presence of protein kinase C inhibitor chelerythrine (Chel) at 3 μmol/L.
Fig. 4Molecular composition of NAD(P)H oxidases in human abdominal aortic aneurysms (n = 5) and aortic segments from risk-factor matched CABG patients (n = 5). Quantitative RT-PCR (TaqMan) of NADPH oxidase subunits p22phox (panel A), nox1 (panel B), nox2 (panel C), nox3 (panel D), nox4 (panel E) and nox5 (panel F) was determined using 20 ng of total RNA. ddCT was used for calculation with GAPDH as a reference gene. Data are expressed as mean relative expression (RQ) ± SD; *-p < 0.05 vs. non AAA; **-p = 0.05; NS — non significant; NE — not expressed.
Fig. 5Relationship of clinical characteristics to vascular superoxide generation from AAA. Panel A. Superoxide production was determined by LGCL (5 μmol/L) in patients with Vanzetto score ≤ 3 and > 3. Data are expressed as mean ± SD. Panel B. Relationships between intra-operatively determined AAA size and NADPH-stimulated superoxide production was (n = 30) determined in AAA segments using LGCL (5 μmol/L) at the site of largest dilatation. Data is analyzed for tertiles of AAA size and non-parametric Kruskal–Wallis ANOVA (p = 0.0018) with post-hoc multiple comparisons was performed.
Major risk factors for atherosclerosis and AAA in studied population in relation to superoxide production. Data are shown as univariate analysis.
| Risk factor | Basal superoxide production (RLU/s/mg dry weight) | p value | |
|---|---|---|---|
| With RF | Without RF | ||
| Male sex | 8.44 ± 2.55 | 29.82 ± 14.16 | 0.22 |
| Hypertension | 31.55 ± 12.73 | 22.56 ± 10.2 | 0.45 |
| Smoking | 37.08 ± 13.89 | 13.38 ± 2.75 | 0.03 |
| Hypercholesterolemia | 40.36 ± 16.23 | 13.89 ± 3.28 | 0.013 |
| Coronary artery disease | 41.79 ± 15.91 | 14.05 ± 4.71 | 0.037 |